Key points from article :
Ochre Bio is a biotech company developing RNA medicines for chronic liver diseases.
It has generated massive amounts of spatial genomics data from freshly donated human livers, and have uncovered hundreds of novel potential liver targets.
Has now closed $9.6M seed financing round led by Khosla Ventures
Participation from Backed VC, Apollo Health Ventures, Selvedge, Hoxton and Hermes-Epitek.
Funding will also expand their deep phenotyping platform to identify and validate new liver targets.
“The liver is a major convergence point in human metabolism and many aspects of health throughout the body," explains Alex Morgan, Partner, Khosla Ventures.
